| Identification | Back Directory | [Name]
4-Morpholineacetamide, N-[2-[(4aS,5aR)-5,5-difluoro-1,4,4a,5,5a,6-hexahydro-5a-methylcycloprop[f]indazol-3-yl]-5-methyl-1H-benzimidazol-6-yl]-N,α-dimethyl-, (αS)- | [CAS]
2655557-54-1 | [Synonyms]
ITK/TRKA-IN-1
4-Morpholineacetamide, N-[2-[(4aS,5aR)-5,5-difluoro-1,4,4a,5,5a,6-hexahydro-5a-methylcycloprop[f]indazol-3-yl]-5-methyl-1H-benzimidazol-6-yl]-N,α-dimethyl-, (αS)- | [Molecular Formula]
C25H30F2N6O2 | [MOL File]
2655557-54-1.mol | [Molecular Weight]
484.55 |
| Hazard Information | Back Directory | [Uses]
ITK/TRKA-IN-1 is a dual inhibitor of IL-2-inducible T-cell kinase (ITK) and tropomyosin receptor kinase A (TRKA) with an IC50 value of 1.0 nM and 96 % inhibition, respectively. | [References]
[1] Bagley SW, et al. Benzimidazole Derivatives. WO2021124155A1. |
|
|